Explore the innovative world of molded glass vials
In 2021, the worldwide capacity of tubular glass vials is not sufficient to cover the global market need.
To face this challenge, pharma, biopharma and veterinary customers have validated multiple sources of glass vials (tubular and molded) to alleviate the strain currently placed on their supply chain. Whether you are developing a COVID-19 vaccine or new treatments in phase IV clinical trials, or are a CMO filling parenteral drugs, we understand that the integration of a new container solution in a manufacturing process designed for tubular glass vials can be a challenge from both a regulatory and a manufacturing point of view. Alongside regulatory hurdles, some adaptations in your manufacturing process may be required to address the differences between tubular and molded glass vials in terms of machinability or inspection. However, the benefits far outweigh the challenges of lack of vials for your drug, impacting time to market and brand confidence. At SGD Pharma, we want to share our expertise and demonstrate the support available to help you avoid supply chain bottlenecks. We have analyzed the current challenges and have the experience to support you to ease the switch to or integration of molded glass vials in your SOP.
Please join Dr. Jingwei Zhang and Carole Grassi Mircich from SGD Pharma to learn about the characteristics of molded and tubular glass and what considerations should be made when evaluating a new glass packaging solution for parenteral drugs. This webinar will then focus on how advances in Type I molded glass vials can help you to overcome some of the challenges of aseptic filling: Tim Wenzel from GILYOS will present his cutting-edge research on lyophilization and the advantages of innovative vial design on heat transfer, and Markus Heinz from Syntegon will discuss his team’s findings when evaluating a new depyrogenation tunnel.
If you work in a pharma or veterinary drug manufacturing lab or a CMO and want to learn more about how to mitigate the risk of supply chain disruptions for glass packaging, please register for our webinar.
Presented by
Jingwei Zhang,
R&D Director
Jingwei ZHANG is currently R&D director of SGD Pharma, based in France.
Previously to this position, he worked for Saint-Gobain for 24 years, as strategic projects manager and R&D portfolio manager. He has a large experience in glass packaging, ranging from products and process development to quality inspection. He is inventor of more than 70 international patents.
Jingwei ZHANG graduated from Harbin Institute of Technology in China, and received his PhD in France.
Carole Grassi Mircich,
Chief Innovation & Development Officer
Carole Grassi Mircich has worked as Chief Innovation & Development Officer at SGD Pharma since May 2019. She is currently in charge of innovation and development as well as strategic marketing, product management, market intelligence, and communication. From May 2017 to June 2019, Carole was Vice President of Marketing & Communication for the group, where she created a new marketing team. Before joining SGD Pharma, Carole spent more than ten years at Rexam Plc, which later became Albéa Packaging. Carole started as Strategy & Business Developer in the UK for the Plastic Division, where she worked with the respective General Managers of the Business Units (Pharma, Cosmetics and Food). Carole then became Cosmetics Category Manager in the Beauty BU and then Marketing Director of the Dispensing Systems BU where she was responsible for market analysis, innovation and product development.
Markus Heinz from Syntegon,
Tim Wenzel ,
Scientist II
Tim Wenzel is a licensed pharmacist in Germany. After graduation from the University of Münster, he pursued his PhD in Pharmaceutical Technology at the University of Erlangen in the Freeze Drying Focus Group led by Henning Gieseler. His research encompassed projects in the fields of controlled ice nucleation, vial heat transfer characteristics, novel packaging materials, miniaturized freeze drying equipment and X-ray microtomography-based product inspection. In 2020, Tim transitioned into the company GILYOS, a contract service provider in the field of freeze drying focusing on formulation and process development.